Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 1/20 | 0.81 |
| ▸ | EGFR | P00533 | 6/20 | 0.68 |
| ▸ | JAK3 | P52333 | 5/20 | 0.68 |
| ▸ | JAK2 | O60674 | 4/20 | 0.68 |
| ▸ | BTK | Q06187 | 4/20 | 0.68 |
| ▸ | JAK1 | P23458 | 3/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.61 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.53 |
| ▸ | TTK | P33981 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18018787 | 0.90 | MAP3K7 (0.77) | MAP3K7EGFRJAK3JAK2BTK | |
| SCHEMBL18018785 | 0.90 | MAP3K7 (1.00) | MAP3K7EGFRJAK3JAK2BTK | |
| SCHEMBL22985926 | 0.86 | MAP3K7 (0.62) | MAP3K7EGFRJAK3JAK2BTK | |
| SCHEMBL18018873 | 0.84 | MAP3K7 (0.68) | MAP3K7EGFRJAK3JAK2BTK | |
| SCHEMBL18018872 | 0.83 | MAP3K7 (0.81) | MAP3K7EGFRJAK3JAK2BTK | |
| SCHEMBL22985914 | 0.82 | MAP3K7 (0.69) | MAP3K7EGFRJAK3JAK2BTK | |
| SCHEMBL18018878 | 0.81 | EGFR (0.79) | MAP3K7EGFRJAK3JAK2BTK | |
| SCHEMBL15453409 | 0.81 | EGFR (1.00) | MAP3K7EGFRJAK3JAK2BTK | |
| SCHEMBL23010735 | 0.81 | MAP3K7 (0.66) | MAP3K7EGFRJAK3JAK2BTK | |
| SCHEMBL15453489 | 0.80 | EGFR (0.72) | MAP3K7EGFRJAK3JAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| EP-3778604-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778605-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10913744-B2 | LRRK2 inhibitors and methods of making and using the same | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| WO-2016130920-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | LRRK2, PARK7, PINK1 | MAP3K7 166/4885EGFR 2819/4885JAK3 2087/4885 |
| US-10913744-B2 | LRRK2 inhibitors and methods of making and using the same | LRRK2, PARK7, PINK1 | MAP3K7 166/4885EGFR 2819/4885JAK3 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.